2020… Ah, what a ride. And no, this is not another text piece joining the chorus of weeping, complaining, and interpreting how the Covid-19 pandemic has devastated drug developers – except those who had an approved antiviral drug available that had some effect against SARS-CoV2. And of course, except those who suddenly fell in love with drug repurposing and actually identified a marketed drug ...

We continue our series with a summary of the Q1/2019 drug repurposing patent discussions in ASSAY and Drug Development Technologies (ahead of print, DOI link here).   WO/2019/004808 (Université Mohammed V Rabat (Morocco) Pyridostigmin restores peripheral nervous system balance in neurodegenerative diseases or after neurotrauma WO/2019/008141 INSERM, CNRS, Université Paris Descarte...

Long time no post here. Still no narrative blogpost b/c virtually all our activities are client-confidential – sorry. But here is a synopsis of the drug repurposing patent discussions that you can soon read in full, in ASSAY and Drug Development Technologies. We shall start with documents published during Q4/2018. Remember, this is only a selection – there are many more that are interesting but di...

This is what to look for in the December 2018 issue of ASSAY and Drug Development Technologies: WO/2018/126000 (Rush University Medical Center, USA) Fibrates (in particular, gemfibrozil) are claimed for LINCL Type 2, a subtype of Batten disease. Much prior art here, some of it ffrom the inventors themselves. WO/2018/126192 (Childrens’ Medical Center Corp., USA) Congenital arteriovenous malform...

Along the lines that have been discussed in a recent Frontiers short paper, here is a list of our patent discussions in the December 2017 drug repurposing special issue of ASSAY and Drug Development Technologies: WO/2017/059389 (Kythera Biopharmaceuticals, USA): Statins as an alternative to liposuction and cryolipolysis WO/2017/060308 (AB Science, France): Masitinib switches to human use WO/201...

Thanks to all who have attended the 6th annual Drug Repositioning, Repurposing and Rescue Conference in Chicago on June 28 & 29. We had two excellent days of presentations, formal discussions, and informal meetings on the sidelines. Also, the well-established close collaboration with Cures Within Reach has been fruitful once more. The potential of this annual event, organized by Arrowhead, ...

If you follow our discussions of patent documents claiming radically new uses for known compounds, published in the issues that ASSAY and Drug Development Technologies dedicates to drug repurposing, you might think that there is a lot of patenting activity going on in this field – indicative of broad commercial interest. Actually, there is significantly more out there. However, the space we can a...

No life science patents, congresses or corporate matters this time. This post goes beyond. It should affect your choice of flights to Arrowhead’s annual Drug Repurposing Conference in June. Imagine you have booked a table at a Chicago restaurant. To get the reservation, you had to pay in advance. While you are waiting for your meal, you are suddenly ordered to give up your table: somebody from ...